Biogen's Alzheimer's drug trial ripe for downside: Analyst

Brian Skorney, analyst at Baird, downgraded Biogen. Skorney joins CNBC's "Power Lunch" team to discuss his call.

Power Lunch,CNBC,business news,finance stock,stock market,news channel,news station,breaking news,us news,world news,cable,cable news,finance news,money,money tips,financial news,stock market news,stocks,